Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical and medical device company that develops, manufactures and markets a broad range of prescription and non-prescription pharmaceutical products that make a meaningful difference in patients’ lives throughout more than 100 countries. Valeant’s primary focus is in the areas of dermatology and eye health. Valeant has an established portfolio of durable products and our strategy is to focus the business on core geographies and therapeutic areas that offer high-growth opportunities. Another critical element of our strategy is business development. We have completed numerous transactions over the past few years, including the acquisition of international eye health organization Bausch + Lomb in 2013, to expand our portfolio and our geographic footprint. We will continue to pursue value-added business development opportunities as they arise. Valeant’s strategic markets are primarily in the United States, Canada, Europe, the Middle East, Latin America, Asia Pacific and Africa.
Type
Public
HQ
Aliso Viejo, US
Founded
1960
Employees
22,000 (est)+31%
Valeant Pharmaceuticals International was founded in 1960 and is headquartered in Aliso Viejo, US

Valeant Pharmaceuticals International Locations

Aliso Viejo, US

Valeant Pharmaceuticals International Metrics

Valeant Pharmaceuticals International Summary

Market capitalization

$5.29 B

Closing share price

$15.6
Valeant Pharmaceuticals International's latest market capitalization is $5.29 B.

Valeant Pharmaceuticals International Market Value History

Valeant Pharmaceuticals International Online Presence

Valeant Pharmaceuticals International News

Valeant Pharmaceuticals International Company Life

You may also be interested in